Targeting high-grade B cell lymphoma with CD19-specific T cells

International Journal of Cancer

Volumn 135, Issue 5, 2014, Pages 1153-1164

  Lehmann, Frank M ^a   Maurberger, Anna ^b   Feicht, Samantha ^c   Helm, Florian ^d   Ladinig, Camilla ^a   Kieback, Elisa ^e   Uckert, Wolfgang ^e   Kammertöns, Thomas ^d   Kremmer, Elisabeth ^c   Mautner, Josef ^a   Gerbitz, Armin ^b   Bornkamm, Georg W ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

B cell lymphoma; CD19; CD4 T cell; T cell therapy

Indexed keywords

CD19 ANTIGEN; EPITOPE; GAMMA INTERFERON; TUMOR REJECTION ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE T CELL THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; LYMPHOCYTE DEPLETION; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE;

B CELL LYMPHOMA; CD19; CD4 T CELL; T CELL THERAPY;

ANIMALS; ANTIGENS, CD19; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE DEPLETION; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED;

EID: 84902547579     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28760     Document Type: Article

References (49)

1. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-5.
2. Kolb HJ,. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-83.
3. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-5.
4. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-35.
5. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-55.
6. Bleakley M, Riddell SR,. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371-80.
7. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-7.
8. Huber CH, Wolfel T,. Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004; 130: 367-74.
9. Offringa R,. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol 2009; 21: 190-9.
10. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.
11. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-57.
12. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-9.
13. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-46.
14. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-20.
15. Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22: 371-83.
16. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-54.
17. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-703.
18. Mumberg D, Monach PA, Wanderling S, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999; 96: 8633-8.
19. Rickert RC, Rajewsky K, Roes J,. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995; 376: 352-5.
20. Rickert RC, Roes J, Rajewsky K,. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 1997; 25: 1317-18.
21. Gerbitz A, Sukumar M, Helm F, et al. Stromal interferon-gamma signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice. PLoS One 2012; 7: e34552.
22. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-9.
23. Lata S, Bhasin M, Raghava GP,. Application of machine learning techniques in predicting MHC binders. Methods Mol Biol 2007; 409: 201-15.
24. Kremmer E, Mysliwietz J, Thierfelder S,. Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice. Clin Exp Immunol 1997; 109: 180-4.
25. Homig-Holzel C, Hojer C, Rastelli J, et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 2008; 205: 1317-29.
26. Kovalchuk AL, Qi CF, Torrey TA, et al. Burkitt lymphoma in the mouse. J Exp Med 2000; 192: 1183-90.
27. Altmann SW, Johnson GD, Prystowsky MB,. Single proline substitutions in predicted alpha-helices of murine granulocyte-macrophage colony-stimulating factor result in a loss in bioactivity and altered glycosylation. J Biol Chem 1991; 266: 5333-41.
28. Lindencrona JA, Preiss S, Kammertoens T, et al. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004; 109: 259-64.
29. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-7.
30. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-8.
31. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33.
32. Spiotto MT, Rowley DA, Schreiber H,. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10: 294-8.
33. Zhang B, Zhang Y, Bowerman NA, et al. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 2008; 68: 1563-71.
34. Engels B, Rowley DA, Schreiber H,. Targeting stroma to treat cancers. Semin Cancer Biol 2012; 22: 41-9.
35. Qin Z, Blankenstein T,. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-86.
36. Ibe S, Qin Z, Schuler T, et al. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001; 194: 1549-59.
37. Kammertoens T, Schuler T, Blankenstein T,. Immunotherapy: target the stroma to hit the tumor. Trends Mol Med 2005; 11: 225-31.
38. Blankenstein T,. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005; 17: 180-6.
39. Poe JC, Minard-Colin V, Kountikov EI, et al. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol 2012; 189: 2318-25.
40. Chung EY, Psathas JN, Yu D, et al. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012; 122: 2257-66.
41. Otero DC, Anzelon AN, Rickert RC,. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol 2003; 170: 73-83.
42. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005; 11: 1490-9.
43. Zhang LH, Xi Z, Chattopadhyaya J,. Medicinal chemistry of nucleic acids. Hoboken, N.J.: John Wiley & Sons, 2011. xxvi, 428 p.
44. Greenberg PD,. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
45. Mizoguchi A, Bhan AK,. A case for regulatory B cells. J Immunol 2006; 176: 705-10.
46. Mauri C, Bosma A,. Immune regulatory function of B cells. Annu Rev Immunol 2012; 30: 221-41.
47. Lund FE, Randall TD,. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010; 10: 236-47.
48. Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010; 116: 3875-86.
49. Cheadle EJ, Hawkins RE, Batha H, et al. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010; 184: 1885-96.